Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $90.93 Consensus Target Price from Brokerages
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12-month target price […]
More Stories
US, Israel Strike Iran
By Sam Dorman President Donald Trump released a video on Feb. 28 stating that the United States had begun “major...
Subaru Recalls Nearly 70,000 Vehicles for Fuel Leak Risk, Issues ‘Park Outside’ Warning
By Mary Prenon Subaru and Kia America have both issued recalls involving thousands of vehicles with elevated risks for accidents...
Melania Trump Set to Make History by Chairing UN Security Council Meeting
By Evgenia Filimianova U.S. First Lady Melania Trump will make history on March 2 when she presides over a U.N....
British Prime Minister Suffers Major By-Election Defeat as Epstein Scandal Casts Pall
By Chris Summers The ruling Labour Party in the UK was beaten into third place on Feb. 26 in a...
US Producer Inflation Rises More Than Expected in January
By Andrew Moran A key pipeline inflation indicator unexpectedly increased in January, potentially signaling higher consumer prices in the coming...
Recurring Unemployment Claims Decline to 1-Month Low
By Andrew Moran In a potential signal that the U.S. labor market could be on the cusp of renewed hiring...